Aspira Women's Health Inc. (AWH)
| Market Cap | 51.91M |
| Revenue (ttm) | 9.03M |
| Net Income (ttm) | -18.04M |
| Shares Out | 10.20M |
| EPS (ttm) | -2.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,620 |
| Open | 4.96 |
| Previous Close | 5.01 |
| Day's Range | 4.90 - 5.17 |
| 52-Week Range | 2.31 - 9.60 |
| Beta | 2.80 |
| Analysts | Buy |
| Price Target | 5.05 (+3.06%) |
| Earnings Date | Nov 9, 2023 |
About AWH
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endoc... [Read more]
Financial Performance
In 2022, AWH's revenue was $8.18 million, an increase of 20.14% compared to the previous year's $6.81 million. Losses were -$27.17 million, -14.19% less than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for AWH stock is "Buy." The 12-month stock price forecast is $5.05, which is an increase of 3.06% from the latest price.
News
Aspira Women's Health Signs Exclusive Sample Procurement Agreement with The University of Oxford
Samples to be used in validating the Company's EndoCheck SM test in development for the diagnosis of endometriosis
Aspira Women's Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations
AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women's health diagnostic t...
Aspira Women's Health® Reports Second Quarter 2023 Financial Results
Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022.
Aspira Women's Health Announces Transition of its Chief Scientific Officer/Chief Operating Officer
AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynec...
Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 14, 2023
AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools...
Aspira Women's Health Regained Compliance with Nasdaq's Minimum Bid Price Requirement
AUSTIN, Texas, June 02, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease di...
Aspira Women's Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests
AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health to Participate at William Blair's 43rd Annual Growth Stock Conference
AUSTIN, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease di...
Aspira Women's Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference
AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health Names Torsten Hombeck as Chief Financial Officer
AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health to Host Investor Day on OvaWatch(SM) and EndoCheck™ Market Opportunities on May 23, 2023
AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health® Reports First Quarter 2023 Financial Results
First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operat...
Aspira Women's Health Announces 1-for-15 Reverse Stock Split
AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health Appoints Three New Members to its Board of Directors
AUSTIN, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...
Aspira Women's Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023
Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company's history
Aspira Women's Health Reports Fourth Quarter and Full Year 2022 Financial Results
2022 total revenue of $8.2 million, an increase of 20% year-over-year
Aspira Women's Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023
AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bio-analytical based women's health company focused on gynecologic disease, today announced that the compa...
Aspira Women's Health Announces National Payer Coverage for OvaWatch
First National Payer to Cover OvaWatch First National Payer to Cover OvaWatch
Aspira Women's Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights
Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021
Aspira Women's Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses
Provides clinical validation for the use of OvaWatch SM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses
Aspira Women's Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio
Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatch SM , through the 2023 Omnibus Spending Bill
Aspira Women's Health Announces the Commercial Launch of OvaWatch(SM)
AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, announced the commercial launch of...
Aspira Women's Health Reports Third Quarter 2022 Financial Results
Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units
Aspira Women's Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022
AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will present and be available ...
Aspira Women's Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women
Data demonstrates the accuracy of Aspira's multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125 in detecting early-stage cancer in women wit...